The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Lizzo has revealed how she dropped a whopping 16% of her body fat during a TikTok livestream on Tuesday — months after publicly denying accusations that she used Ozempic. The “Truth Hurts” songstress, ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...

GLP-1s have gone so far as to disrupt the food, clothing, and ... injectable drugs indicated for people with obesity—such as Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda ...

There are many reasons for this, such as dietary choices, cultural norms, and socioeconomic factors that influence food accessibility ... So toss the weight chart in the trash and consider ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

GLP-1 drugs include Ozempic and Rybelsus, both of which have been approved by the Food and Drug Administration to treat diabetes. They also include Saxenda and Wegovy, which the FDA approved for ...

Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or compounded, versions of the treatment, according to the Danish pharma ...